Search Results

Baxter Announces U.S. FDA 510(K) Clearance of AK 98 Hemodialysis Machine

Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 (AK 98) dialysis machine, which is designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments.

Baxter to Present at Oppenheimer 31st Annual Healthcare Conference

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021.  Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through September 13, 2021.  

Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that they have entered into an agreement for Baxter BioPharma Solutions (BPS) to provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021.

Living Well with Kidney Disease

An estimated 850 million people have kidney disease globally; nearly 10.5 million of these individuals require dialysis or a kidney transplant.1 Each of these remarkable people have a story, a family and an adventure ahead of them; they deserve to live well with kidney disease.

Baxter Declares Quarterly Dividend

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.245 per share of common stock. The dividend is payable on April 1, 2021, to shareholders of record as of February 26, 2021. The indicated annual dividend rate is $0.98 per share of common stock.  About Baxter

Baxter Appoints Dr. David Wilkes to Its Board and Albert Stroucken as Lead Independent Director

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed David S. Wilkes, M.D., dean, University of Virginia School of Medicine, and co-founder and chief scientific officer of biotech start-up ImmuneWorks Inc., to its board of directors. Dr. Wilkes will serve on Baxter's Quality, Compliance and Technology Committee. Additionally, Baxter has appointed Albert P.L.

American Diabetes Association and the Baxter International Foundation Partner in Health Equity Initiative to Address Barriers to Diabetes Management

Today, the American Diabetes Association® (ADA) and the Baxter International Foundation, the philanthropic arm of Baxter International Inc., announced a new partnership as part of the ADA’s Health Equity Now (HEN) platform to address health disparities for people with diabetes in Chicago’s underserved Black communities.

Baxter Reports Fourth-Quarter and Full-Year 2020 Results

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the fourth quarter and full year ended December 31, 2020, and provided its financial guidance for 2021. 

Baxter to Present at SVB Leerink 10th Annual Global Healthcare Conference

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021.  Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time.   The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through May 25, 2021.

Baxter BioPharma Solutions Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, today announced that Baxter BioPharma Solutions (BPS) has entered into an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M™ adjuvant. Baxter BioPharma Solutions is a premier contract manufacturing organization that specializes in parenteral (injectable) pharmaceuticals, including vaccines.